{"id":784,"date":"2021-01-28T11:22:47","date_gmt":"2021-01-28T11:22:47","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=784"},"modified":"2021-01-28T11:22:47","modified_gmt":"2021-01-28T11:22:47","slug":"22-jan-2021-tocilizumab-tcz-plus-soc-was-not-superior-in-improving-clinical-outcomes-at-15-days","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/22-jan-2021-tocilizumab-tcz-plus-soc-was-not-superior-in-improving-clinical-outcomes-at-15-days\/","title":{"rendered":"(22 Jan 2021) Tocilizumab- TCZ plus SoC was not superior in improving clinical outcomes at 15 days"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1001\/jama.2021.0202<\/p>\n<p class=\"\">NCT04403685-A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed follow-up. All patients in the tocilizumab group and two in the standard care group received tocilizumab. 18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard care group were receiving mechanical ventilation or died at day 15 (odds ratio 1.54, 95% confidence interval 0.66 to 3.66; P=0.32). Death at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group (odds ratio 6.42, 95% confidence interval 1.59 to 43.2). Adverse events were reported in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocilizumab.&nbsp; In patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial https:\/\/doi.org\/10.1001\/jama.2021.0202 NCT04403685-A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/22-jan-2021-tocilizumab-tcz-plus-soc-was-not-superior-in-improving-clinical-outcomes-at-15-days\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(22 Jan 2021) Tocilizumab- TCZ plus SoC was not superior in improving clinical outcomes at 15 days&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/784"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=784"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/784\/revisions"}],"predecessor-version":[{"id":785,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/784\/revisions\/785"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}